Abstract. Cabergoline (CG) is a dopamine agonist that inhibits the secretion of prolactin (PRL) and growth hormone. In the present study, we evaluated the in vivo effect of CG on PRL secretion and the pituitary tumor induced by estrogen. Estrogen was administered by subcutaneous injection to 4-weekold Fischer 344 rats weekly for 10 weeks to induce tumors. On the last day of estrogen administration, doses of either CG or bromocriptine (BC), 0.6 mg/kg, were administered as a single oral route or chronically, given every third day. Sera and pituitary tumors were sampled on each treatment schedule. Serum levels of PRL were measured and the pituitary glands were weighed. Immunohistological evaluation was performed by optical and electron microscopy. A single dose of CG significantly inhibited the serum levels of PRL for 6 days. Following a single dose of BC, the PRL level was significantly inhibited only at 6 hours' postadministration.
also exhibits a potent PRL-lowering effect and an antitumor effect in animals and humans [10] [11] [12] [13] [14] [15] [16] [17] . Its mechanism of action in reducing tumor size has never been reported.
We also studied the effect of CG on estrogen-induced rat pituitary tumors in vitro. In that study CG showed a greater action against cultured pituitary tumors than BC [18] .
We conducted the present study to examine the changes in serum PRL values and pituitary tumor weight, and analyzed tumor histology after CG treatment by morphologic technique with immunohistochemistry and immunoelectron microscopy, to further investigate the effects of CG in treating pituitary tumors induced in the rat by estrogen.
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Materials and Methods

Induction of rat pituitary tumor
Female F344 rats (Charles River Japan Co. Ltd, Yokohama, Japan) 4 weeks old were used. They were housed a room with controlled light and temperature and had free access to laboratory chow and tap water (24 °C and light from 0600 to 2000 h). Pituitary tumors were induced by administering a subcutaneous injection of 2 mg estradiol-17/3 (E2) in 0.2 ml sesame oil weekly for 10 weeks. No additional estrogen treatment was given thereafter.
Drug administration
To examine the effect of a single dose of each agent on PRL levels, rats were administered either CG orally at a dose of 0.6 mg/kg in 0.2 ml sesame oil, the same dose of BC, or the vehicle sesame oil (0.2 ml), as control. Blood samples were collected from the tail vein under inhalation anesthesia 2 h before administering the single dose and again at 6, 12, 18, and 24 h after the administration, and again at 2, 3, 4, and 6 days.
To examine the effects of the drugs on PRL levels after their chronic oral administration, the rats were administered CG, BC or sesame oil at the doses mentioned by gavage every third day, and were killed by decapitation at 15, 30 and 60 days. The collected sera were stored at -20 °C for radioimmunoassay (RIA) of PRL. The pituitary tissues were removed, weighed, and prepared for examination by light and electron microscopy.
Hormone assays
The PRL standards (NIDDK rat PRL RP-3, AFP-4459B) were provided by the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK Bethesda, MD) and the anti rat PRL serum (HAC-RT26-01RBP85) by Dr. Wakabayashi (Institute of Molecular and Cellular Regulation, Gunma University, Maebashi, Japan). Radioiodinated rat PRL was purchased from Du Pont /NEN Research Products (Boston, MA) and goat antirabbit IgG was purchased from Bio Makor (Rehovot, Israel). RIAs of PRL were performed by a double antibody method. In our assay system of rat PRL, the detection For immunoelectron microscopic observations, the sections mounted on nickel mesh were etched with 10% H2O2 for 10 min, then rinsed 3 times in phosphate buffer saline (PBS) for 10 min. They were treated with 1 % bovine serum albumin in PBS for 40 min and incubated overnight at 4 °C with a dilution of 1:3000 of anti-rat PRL serum (HAC-RT26-01RBP85). After rinsing in PBS, protein-A gold (20-nm particles; EY Lab., Inc., San Mateo, CA) was applied at room temperature for 30 min. They were again rinsed in PBS and distilled water and allowed to dry in air. Sections mounted on copper or nickel mesh were stained with uranyl acetate and lead citrate and observed with an Hitachi H-7000 electron microscope (Tokyo, Japan). For morphometric analysis by immunoelectron microscopy, cellular and nuclear area, number of PRL-immunoreactive granules per ,um2 cytoplasm, and maximal diameter of these granules were measured from photographic prints. 3) . However, no significant reduction in serum PRL levels was observed in the group administered BC.
Pituitary weight
The mean pituitary weight of the rats prior to the chronic administration of the agents was 242.2 mg (Fig. 4) . The pituitary weight in the control group gradually increased for 30 days after the final dose of estrogen.
CG significantly reduced the pituitary weight on day 15, and it was 29% of the control value on 60 days. In contrast, the weight of the pituitary glands of the BC-treated rats did not differ from that of control. Thus, BC did not 
Light microscopy
Pituitary tumors in the control group appeared as diffuse sheets of similar cells traversed by vascular channels with abundant pools of blood. The tumor tissue treated with CG or BC was partially occupied by acellular spaces and fibrosis, thought to be due to partial necrosis. No such feature was detected in control tumor tissue (Fig. 5) .
The PRL tumor cell treated with cabergoline had a shrunken cytoplasm, compared with that of control group (Fig. 6) . From the immunohistochemical analysis for PRL, the incidence of PRL cells per about 1,000 cells was 70% in control group, and did not differ significantly among the three groups.
Electron microscopy Conventional electron microscopic examination verified a marked reduction in the size of individual cells and that of secretory granules in the tumor cells treated with CG as compared with the control (Fig. 7A, B) . Degenerative cells in tumor tissue treated with CG were scattered among intact tumor cells (Fig. 7B) . From observation by immunoelectron microscopy, most of the tumor cells were found to be immunoreactive with PRL (Fig. SA, B) . Ultrastructural changes in tumor cells containing PRL-immunoreactive granules (PRL tumor cells) were the same as those observed by routine electron microscopy. PRL tumor cells with vacuolized and fragmented rough endoplasmic reticula were also observed (Fig. 9A) . In some PRL cells adjacent to the area of fibrosis, condensed and fragmented nuclei and lysis of cytoplasm were also recognized (Fig. 9B) . Such lysosomal crinophagic structures were often observed in degenerative cells treated with CG. No degenerative changes were detected in the control group.
The ultrastructural changes observed on immunoelectron microscopy were morphometrically analyzed between control and CG treatment except for the cells showing degenerative features (Table 1, Fig. 10 ). CG significantly reduced the size of individual cells as compared with control. However, no significant changes in the area of the nucleus were observed between the two groups. Accordingly, the nucleoplasmic ratio was more marked in the CG group than in the control group. In addition, CG significantly reduced the maximal diameter of the PRL-immunoreactive secretory granules and increased the number of granules per unit cytoplasmic area ( Table 1) . Analysis of diameter distribution revealed that secretory granules with a smaller diameter occupied a greater part of the population in the CG-treated group than in the control group (Fig. 10) . Chronic administration of estrogen to rats ultimately produces a PRL-secreting pituitary tumor with dopamine receptors similar to those of a normal pituitary [8, [19] [20] [21] . PRL secretion is regulated via dopamine and GAP (gonadotropin releasing hormone associated peptide).
The nature of the intracellular messenger has not been completely elucidated [22] . BC binds with the D2 receptor and inhibits PRL exocytosis via an inhibition of adenylate cyclase activity and a reduction in the level of cyclic AMP (adenosine monophosphate) [9, 23] , leading to the intracellular accumulation of PRL. As a result, the synthesis of PRL and of DNA are decreased, leading to a reduction in mitotic activity. Calcium channels and inositol triphosphate signaling seem to be involved in this signal transduction.
A deg- Immunoelectronmicrograph showing various stages of cell necrosis. Bar=2 µm. Vacuolized and fragmented rough endoplasmic reticula are observed in PRL cell (arrows, A). Condensed and fragmented nucleus (Nu) and lysosome (arrow head) in the cytoplasm are also observed in the PRL cell adjacent to the fibrosis (B). CG is a new oral dopaminergic agent that shows a potent PRL-lowering effect in rats and humans [11] [12] [13] [14] 17, 25] . It inhibits the tumorigenesis of the rat pituitary gland stimulated by estrogen and the enlargement of the estrogen-induced rat pituitary tumor [10, 16] .
The inhibitory effect following a single oral dose of CG was more potent than that of BC, persisting for 6 days, in general agreement with other findings [10, 11] . Those authors found that a single oral dose of CG induced a marked fall in serum PRL level that persisted for 72 h in rats [10] , and for 7 days in humans [15] .
The disappearance half-life of CG is biphasic like that of other ergoline derivatives, being 7.5 (T 1/24 -24 h) and 65 h (T 1/2 24_120 h). The corresponding values for BC are 6.5 and 67.9 h, respectively.
Thus, CG and BC have similar half-lives.
The bioavailability of CG by the oral route ranges from 7.4-17.8% in humans, while that of BC is about 6%
[26]. The affinity of CG for binding to dopamine receptors in the strial region of rat brain exceeds that of BC [27] . The prolonged effect of CG on serum PRL levels may be due to its improved bioavailability and a higher affinity for dopamine receptors as compared with BC. Chronic oral administration of CG also induced a marked decrease in serum PRL levels, with values returning to the normal range 60 days after treatment.
A [3, 4] , nucleolar change i.e. pycnosis, karyorrehexis and karyolysis [3] , and reduction in the size of organelles involved in PRL synthesis [5, 7] .
In our comparison of CG and BC, we used the same oral dose of each agent. At that dose CG, but not BC, was effective in reducing the weight of pituitary tumor. This indicates that a higher dose of BC is required to obtain an antitumor effect. This seems to be supported by the finding that the administration of CG every third day was as effective as daily BC administered at a five-fold higher dose than CG in suppressing the development of estrogen-induced pituitary tumor [10] . The present study also demonstrated that CG reduced the size of tumor cells, produced tumor cell necrosis, and led to the disappearance of pools of blood in tumor tissue. A decrease in tumor weight may also have resulted.
Such effects of CG agree with those observed with BC therapy [7] , which suggests a similar action of CG and BC.
Morphologic studies revealed that CG reduced the size of PRL-immunoreactive secretory granules and increased the number of granules per unit area of cytoplasm.
These findings accorded well with those of BC in previous studies and of castrated rats, which may due to the decreased activity of Golgi apparatus followed by change in the processing and maturation of secretory granules [5, 8, [34] [35] [36] . The present results therefore suggest that CG preferentially inhibits the maturation of the PRL secretory granule.
In conclusion, the antitumor effect of CG resembled that of BC. CG exhibited superior features including a prolonged-lowering of PRL, a good antitumor effect against estrogen-induced rat pituitary tumors, and can be used at a lower dose and frequency of administration.
